- General oncology. Cancer treatment in Israeli clinics is based on personalized medicine. Every patient receives an individual treatment protocol developed according to the particular characteristics of the disease. This allows for treatment of cancer even in the later stages.
- The professor leads a multidisciplinary team that treats osteosarcomas in accordance with advanced protocols with preservation of affected limbs.
Diseases Treated by the Physician:
Tel Aviv University, Professor, Faculty of Medicine
Private practice at Top Ichilov Hospital
Head of the Bone and Soft Tissue Tumour Division, Department of Oncology, Ihilov Medical Center
Israel Defence Forces doctor, head of the military commission of the Northern Military District
Gustave Roussy Institute of Oncology (France, Paris), fellowship in the treatment of bone and soft tissue sarcomas
New York Hospital Medical Centre (USA, New York), residency in radiation therapy and brachytherapy
Tel Aviv University, internship and certification in oncology
Hebrew University of Jerusalem, Faculty of Medicine
Israeli Society for Clinical Oncology and Radiotherapy (ISCORT)
American Society of Clinical Oncology (ASCO)
European Society for Medical Oncology (ESMO)
European Musculo-Skeletal Oncology Society (EMSOS)
Connective Tissue Oncology Society (CTOS)
“The more the science develops, the more personalized becomes the treatment that we offer to every patient. Today, we have more opportunities to cure lung cancer, and in the future, thanks to the revolution in oncology, immunotherapy will become one of the common cancer treatment methods alongside surgery, radiation therapy, and chemotherapy. We have been testing various combinations of immunotherapy and chemotherapy in order to better control the disease with all available methods.
Targeted biological drugs were developed to detect and neutralize specific proteins on the tumor surface so their effect on the healthy organs is minimal. This is the new, game-changing stage of treating various types of lung cancer: immunologic drugs developed by molecular biology experts help personalize treatment and increase its quality.
Only 30 years ago, some types of cancer, including non-small cell lung cancer, were incurable. Nowadays, we can stimulate the patient’s immune system and offer them more effective and less toxic treatment. In addition, the development of oncology promotes personalization of treatment. This ensures better therapy results and increases the patients’ survival.
Treatment that suits one patient may be contraindicated for another patient. We have to make an informed choice, carry out thorough molecular genetic testing to select treatments with the best chances. This is why the treatment program is developed by a team of experts including pulmonologists, thoracic surgeons, thoracic imaging specialists, and a pathologist specializing in lung cancer, as well as medical oncologists and radiation therapists that treat lung cancer.”
Publications in Foreign Medical Journals:
Complete list (159):
Author’s Name: Dmitry Finkelstein